Adamsbrown Wealth Consultants’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$685K Buy
571
+103
+22% +$105K 0.13% 70
2026
Q1
$430K Buy
468
+35
+8% +$35.5K 0.11% 80
2025
Q4
$466K Buy
433
+24
+6% +$22.9K 0.13% 71
2025
Q3
$312K Buy
409
+110
+37% +$81.9K 0.09% 87
2025
Q2
$233K Buy
299
+4
+1% +$3.11K 0.07% 96
2025
Q1
$244K Buy
295
+30
+11% +$25K 0.08% 85
2024
Q4
$205K Buy
265
+14
+6% +$11.6K 0.07% 94
2024
Q3
$222K Buy
+251
New +$226K 0.08% 83

Other funds holding LLY

Adamsbrown Wealth Consultants's LLY Position: Q2 2026 in Review

Adamsbrown Wealth Consultants increased its Eli Lilly (LLY) stake by 22% in Q2 2026, buying an estimated $105K and bringing the position to 571 shares worth $685K. The position accounts for 0.13% of the portfolio, ranked #70.

Adamsbrown Wealth Consultants first reported a position in LLY in Q3 2024 and has held it in 8 quarters since. 1,640 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Adamsbrown Wealth Consultants held 571 shares of Eli Lilly worth $685K as of Q2 2026.
  • Adamsbrown Wealth Consultants bought 103 Eli Lilly shares in Q2 2026, an estimated $105K.
  • Eli Lilly made up 0.13% of Adamsbrown Wealth Consultants's portfolio in Q2 2026, its #70 holding.
  • Adamsbrown Wealth Consultants first reported a position in Eli Lilly in Q3 2024 and has held it in 8 quarters since.
  • 1,640 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Adamsbrown Wealth Consultants's 13F filing for Q2 2026, filed 9 Jul 2026.